II study to determine if Danazol is an Anti-D agent when used in combination
with Anti-D for the treatment of ITP
Mount Sinai St. Luke's, Mount Sinai Roosevelt, and Mount Sinai Beth Israel's Clinical Research Office is conducting a research study for the combination of anti-Rh(D) and danazol in patient with Immune Thrombocytopenic Purpura (ITP). This study will determine if danazol is an anti-Rh(D)-sparing agent and that the addition of danazol to anti-Rh(D) may decrease the requirement for anti-Rh (D) and even conclude the need for continued anti-Rh(D) after one year.
Criteria for Participation:
Patients diagnosed with Immune thrombocytopenic purpura at least 18 years of age who have platelets less than 30,000/µl.
Benefit of Participation:
There may or may not be direct medical benefit to you. We hope the information learned from this study will benefit other subjects with ITP in the future.